BridgeMD
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
EU CTIS ID: 2022-500933-10-00
What this study is testing
Evaluate the effect of aspirin 150mg daily initiated between 9 and 15(+6 days) weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia in nulliparous pregnant women after assisted reproductive technology.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Nulliparous women aged 18 years or more
- Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor
- Singleton pregnancy
- Evolutive pregnancy between 9 and 15 (+6 days) weeks of gestation
- Women affiliated to a French Social Security Insurance or equivalent social protection
- Written informed consent
You likely can't join if
- Major fetal abnormality
- Regular treatment with aspirin (including antiphospholipid syndrome)
- Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)
- Women protected by law.
- Patient included in another drug study or another interventional study which could interfere with the results of the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.